9(6)06
Nauka innov. 2013, 9(6):61-72
https://doi.org/10.15407/scin9.06.061
D.F. Gluzman1, L.M. Sklyarenko1, M.P. Zavelevich1, S.V. Koval1, T.S. Ivanovskaya1, L.Yu. Poludnenko1, N.I. Ukrainskaya1, G.D. Тelegeev2, M.V. Dybkov2, L.A. Polischuk2
1 Institute of Experimental Pathology, Oncology and Radiobiology. RE Kavetsky NAS of Ukraine, Kyiv
2 Institute of Molecular Biology and Genetics, NAS of Ukraine, Kyiv
Complex Diagnosis of Myeloid Neoplasms in Regional Oncological Centers
Section: Scientific and Technical Innovative Projects of National Academy of Sciences of Ukraine
Language: Ukrainian
Abstract: The complex diagnostic system involving cytomorphological, cytochemical, immunocytochemical and molecular genetic study was evaluated and proved to be effective in examining the patients of oncological centers in Ukraine.
Key words: myeloid neoplasms, chronic myelogenous leukemia, polycythemia vera, primary myelofibrosis, essential thrombocythemia, cytomorphological diagnosis, reverse transcriptase polymerase chain reaction.
Full Text (PDF)
References:
1. Swerdlow S.H., Campo E., Harris N.L. et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press. 2008. 439 p.
2. Jaffe E.S., Harris N.L., Stein H., Vardiman Y.W. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press. 2001. 351 p.
3. Murati A., Brecqueville M., Devillier R. et al. Myeloid malignancies: mutations, models and management. BMC Cancer. 2012. V. 12. P. 304.
https://doi.org/10.1186/1471-2407-12-304
4. Baxter E.J., Scott L.M., Campbell P.J. et al. Acquired mutation of the tyrosine kinase JAK2 in human myelo proliferative disorders. Lancet. 2005. V. 365, No. 9464. P. 1054-1061.
https://doi.org/10.1016/S0140-6736(05)74230-6
5. Kralovics R., Passamonti F., Buser A.S. et al. A gain-offunction mutation of JAK2 in myeloproliferative di s orders. N Engl J Med. 2005. V. 352, No. 17. P. 1779-1790.
https://doi.org/10.1056/NEJMoa051113
6. Zhao R., Xing S., Li Z. et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol. Chem. 2005. V. 280, No. 24. P. 22788-22792.
https://doi.org/10.1074/jbc.C500138200
7. Levine R.L., Wadleigh M., Cools J. et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005. V. 7, No. 4. P. 387–397.
https://doi.org/10.1016/j.ccr.2005.03.023
8. Dybkov M.V., Gartovs'ka I.R., Telegejev G.D., Maljuta S.S. Rozrobka test-systemy dlja vyjavlennja mutacii' V617F gena jak2 u hvoryh na hronichni mijeloproliferatyvni zahvorjuvannja. Nauka innov. 2009, 5(6):59-63 [in Ukrainian].
https://doi.org/10.15407/scin5.06.059